Sarepta Therapeutics, Inc. (SRPT) Stock Forecast
Data as of Jun 19, 2026Healthcare · Current price $17.50 (+3.15%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 12, 2026 | Uy Ear | Mizuho Securities | $31.00 | +77.1% |
| Mar 3, 2026 | Ilya Zubkov | Loop Capital Markets | $25.00 | +42.9% |
| Mar 3, 2026 | Andrew Tsai | Jefferies | $30.00 | +71.4% |
| Nov 5, 2025 | Uy Ear | Mizuho Securities | $26.00 | +48.6% |
| Nov 4, 2025 | Brian Skorney | Robert W. Baird | $15.00 | -14.3% |
| Oct 30, 2025 | Biren Amin | Piper Sandler | $16.00 | -8.6% |
| Sep 9, 2025 | Joseph Schwartz | Leerink Partners | $15.00 | -14.3% |
| Aug 15, 2025 | David Hoang | Deutsche Bank | $12.00 | -31.4% |
| Jul 22, 2025 | Gena Wang | Barclays | $18.00 | +2.9% |
| Jul 21, 2025 | Kostas Biliouris | BMO Capital | $50.00 | +185.7% |
| Jul 19, 2025 | Joseph Schwartz | Leerink Partners | $10.00 | -42.9% |
| Jun 17, 2025 | Yanan Zhu | Wells Fargo | $75.00 | +328.6% |
| Jun 16, 2025 | Kristen Kluska | Cantor Fitzgerald | $20.00 | +14.3% |
| Jun 15, 2025 | Kostas Biliouris | BMO Capital | $70.00 | +300.0% |
| Nov 27, 2024 | Biren Amin | Piper Sandler | $182.00 | +940.0% |
| Nov 27, 2024 | Gil Blum | Needham | $202.00 | +1054.3% |
| Nov 7, 2024 | Brian Skorney | Robert W. Baird | $193.00 | +1002.9% |
| Nov 7, 2024 | Kristen Kluska | Cantor Fitzgerald | $167.00 | +854.3% |
| Oct 21, 2024 | Andrew Tsai | Jefferies | $165.00 | +842.9% |
| Aug 8, 2024 | Gavin Clark-Gartner | Evercore ISI | $179.00 | +922.9% |
Top Analysts Covering SRPT
SRPT vs Sector & Market
| Metric | SRPT | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 3.82 | 2.24 | 2.40 |
| Analyst Count | 11 | 8 | 18 |
| Target Upside | +65.1% | +11475.0% | +16.8% |
| P/E Ratio | -3.09 | 3.93 | 35.58 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $340M | $436M | $669M | 14 |
| 2026-09-30 | $304M | $390M | $605M | 7 |
| 2026-12-31 | $337M | $432M | $671M | 11 |
| 2027-03-31 | $298M | $382M | $593M | 11 |
| 2027-06-30 | $305M | $391M | $606M | 7 |
| 2027-09-30 | $308M | $395M | $613M | 8 |
| 2027-12-31 | $313M | $401M | $622M | 7 |
| 2028-12-31 | $1.42B | $1.42B | $1.43B | 14 |
| 2029-12-31 | $1.10B | $1.44B | $1.70B | 9 |
| 2030-12-31 | $1.11B | $1.44B | $1.71B | 13 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $0.05 | $0.69 | $1.71 | 8 |
| 2026-09-30 | $0.28 | $0.39 | $0.67 | 3 |
| 2026-12-31 | $0.57 | $0.79 | $1.36 | 6 |
| 2027-03-31 | $0.18 | $0.25 | $0.42 | 3 |
| 2027-06-30 | $0.40 | $0.57 | $0.97 | 5 |
| 2027-09-30 | $0.38 | $0.53 | $0.91 | 3 |
| 2027-12-31 | $0.47 | $0.66 | $1.13 | 6 |
| 2028-12-31 | $-2.51 | $0.82 | $3.84 | 12 |
| 2029-12-31 | $0.64 | $0.92 | $1.13 | 10 |
| 2030-12-31 | $0.81 | $1.16 | $1.43 | 5 |
Frequently Asked Questions
What is the analyst consensus for SRPT?
The consensus among 11 analysts covering Sarepta Therapeutics, Inc. (SRPT) is Sell with an average price target of $24.63.
What is the highest price target for SRPT?
The highest price target for SRPT is $205.00, set by Biren Amin at Piper Sandler on 2024-06-26.
What is the lowest price target for SRPT?
The lowest price target for SRPT is $10.00, set by Joseph Schwartz at Leerink Partners on 2025-07-19.
How many analysts cover SRPT?
11 analysts have issued ratings for Sarepta Therapeutics, Inc. in the past 12 months.
Is SRPT a buy or sell right now?
Based on 11 analyst ratings, SRPT has a consensus rating of Sell (3.82/5) with a +65.1% upside to the consensus target of $24.63.
What are the earnings estimates for SRPT?
Analysts estimate SRPT will report EPS of $0.69 for the period ending 2026-06-30, with revenue estimated at $436M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.